Adlai Nortye (ANL) Total Non-Current Liabilities (2022 - 2025)

Adlai Nortye's (ANL) quarterly Total Non-Current Liabilities came in at $1.1 million in Q4 2025, up 165.18% year-on-year from $425000.0 in Q4 2024, and up 338.52% on a QoQ basis from $257000.0 in Q2 2025.

Adlai Nortye (ANL) Total Non-Current Liabilities (2022 - 2025) Analysis & Trends

Adlai Nortye (ANL) has 4 years of Total Non-Current Liabilities data on file, last reported at $1.1 million in Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 165.18% year-over-year to $1.1 million in Q4 2025; TTM through Dec 2025 was $1.1 million, a 165.18% increase from a year earlier, with the FY2025 full-year figure at $1.1 million, up 165.18% from the prior year.
  • Total Non-Current Liabilities for Q4 2025 stood at $1.1 million, up from $257000.0 in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for ANL reached as high as $5.5 million in Q4 2023 and fell as low as $257000.0 in Q2 2025.
  • Historically, Total Non-Current Liabilities has averaged $1.7 million across 4 years, with a median of $1.1 million in 2025.
  • Across the five-year window, Total Non-Current Liabilities soared 342.48% in 2023 and tumbled 92.23% in 2024, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $1.2 million in 2022, then surged by 342.48% to $5.5 million in 2023, then tumbled by 92.23% to $425000.0 in 2024, then jumped by 165.18% to $1.1 million in 2025.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $1.1 million in Q4 2025, $257000.0 in Q2 2025, and $425000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 4.45 Mn
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 110.28 Mn
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 19.49 Mn
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 1.98 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - 746.94 Mn
10 Adlai Nortye 1.16 Bn 1.15 Bn - 1.13 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 1.13 Mn
Jun 30, 2025 257,000.00
Dec 31, 2024 425,000.00
Dec 31, 2023 5.47 Mn
Dec 31, 2022 1.24 Mn